Cargando…
Metformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome
Non-alcoholic fatty liver disease (NAFLD) is a common yet little recognized health problem in women with polycystic ovary syndrome (PCOS). In a retrospective setting, we investigated the effects of metformin treatment on the hepatic steatosis index (HSI) as a readily available biomarker panel for NA...
Autores principales: | Riemann, Annika, Blaschke, Martina, Jauho-Ghadimi, Annukka, Siggelkow, Heide, Gollisch, Katja Susanne Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331742/ https://www.ncbi.nlm.nih.gov/pubmed/35893386 http://dx.doi.org/10.3390/jcm11154294 |
Ejemplares similares
-
Hepatic steatosis in women with polycystic ovary syndrome
por: Hong, Xinyu, et al.
Publicado: (2023) -
Prevalence of hepatic steatosis in women with polycystic ovary syndrome
por: Karoli, Ritu, et al.
Publicado: (2013) -
Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome
por: Jobira, Beza, et al.
Publicado: (2021) -
Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
por: Wang, Dongxu, et al.
Publicado: (2023) -
Ovulation induction by metformin among obese versus non-obese women with polycystic ovary syndrome
por: Al-Ruthia, Yazed Sulaiman, et al.
Publicado: (2017)